Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/30502
Title: Effects of ankaferd hemostat on helicobacter pylori strains and antibiotic resistanc
Authors: Çiftçiler, R.
Koluman, A.
Haznedaroğlu, İ.C.
Akar, N.
Keywords: Ankaferd blood stopper
Gastrointestinal bleeding
Helicobacter pylori
amoxicillin
ankaferd
clarithromycin
hemostatic agent
metronidazole
unclassified drug
ankaferd blood stopper
antiinfective agent
plant extract
antibacterial activity
antibiotic resistance
antibiotic sensitivity
Article
bacterium identification
bacterium isolation
controlled study
disk diffusion
drug efficacy
drug response
gastritis
Helicobacter infection
human
nonhuman
RNA sequence
stomach ulcer
drug effect
gastrointestinal disease
microbial sensitivity test
microbiology
Anti-Bacterial Agents
Drug Resistance, Bacterial
Gastrointestinal Diseases
Helicobacter Infections
Humans
Microbial Sensitivity Tests
Plant Extracts
Publisher: Turkiye Klinikleri Journal of Medical Sciences
Abstract: Background/aim: Ankaferd hemostat (ABS; Ankaferd blood stopper, İstanbul, Turkey) is a folkloric medicinal plant extract. The aim of this study was to determine the effect of Ankaferd hemostat (ABS) on the fate of Helicobacter pylori strains. The study also aims to determine alterations in the antimicrobial resistance of three different H. pylori strains in response to ABS exposure. Materials and methods: H. pylori Strain 1 was obtained from the culture collection ATCC 43504 and passaged three times for viability. Strain 2 was isolated from a gastric ulcer patient and Strain 3 was isolated from a gastritis patient. 1% of ABS was added to all of the strains and antimicrobial susceptibility was observed on 30 and 60 min after application. Results: The efficacy of ABS solutions in achieving significant logarithmic reduction in foodborne pathogens of H. pylori was observed in this study. This study showed that ABS has antibacterial (Anti-H. pylori) effects. Conclusion: Our present study indicated, for the first time, that ABS could act against H. pylori. ABS is clinically used for the management of GI bleeding due to benign and malignant GI lesions. Thus, the possible anti-H. pylori effect of ABS shall expand the therapeutic spectrum of the drug in GI lesions in relation to H. pylori infection such as peptic ulser disease (PUD) and lymphoid tissue (MALT) lymphomagenesis. © TUBİTAK.
URI: https://hdl.handle.net/11499/30502
https://doi.org/10.3906/sag-1807-206
ISSN: 1300-0144
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Teknoloji Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
sag-49-1-51-1807-206.pdf203.03 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

7
checked on Nov 21, 2024

Page view(s)

46
checked on Aug 24, 2024

Download(s)

10
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.